StockData
Ironwood Pharmaceuticals Inc logo

Ironwood Pharmaceuticals Inc (IRWD) company profile

IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3062% below fair value
$4.87+0.02 (+0.41%)

Close on Nov 17, 2026Market cap $804.72MP/E 6.3Yield –

About Ironwood Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Ironwood Pharmaceuticals, Inc. is a biotechnology company that researches, develops, and commercializes therapies for individuals affected by gastrointestinal and rare diseases. Its primary commercial medicine is linaclotide, branded as LINZESS and CONSTELLA, which is a guanylate cyclase type C agonist. The business also advances clinical-stage drug candidates, notably apraglutide for short bowel syndrome. Its treatments serve adult and pediatric patients with conditions such as irritable bowel syndrome with constipation, chronic idiopathic constipation, and functional constipation.

The company was incorporated in Delaware and operates globally through strategic collaborations with pharmaceutical partners across North America, Europe, and Asia. Its commercialized product is distributed in multiple international markets, including the United States, Canada, Mexico, China, and Japan, alongside various European nations such as the United Kingdom, Italy, and Spain. Manufacturing and distribution activities rely on networks of third-party contract suppliers and regional pharmaceutical partners.

Summary of the business section of Ironwood Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Ironwood Pharmaceuticals Inc
Founded
1998
Headquarters
Boston, MA
Address
100 Summer Street, Suite 2300 02110
Phone
(617) 621-7722
Employees
100, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
IRWD
Exchange
Nasdaq
IPO date
Feb 4, 2010
Shares outstanding
165M, Jul 31, 2026
Public float
$102.69M, Jun 30, 2025
Filer category
Accelerated filer<br>Smaller reporting company
SEC CIK
1446847
CUSIP
46333X108
ISIN
US46333X1081
FIGI
BBG000GBZ3J2
Share class FIGI
BBG001SNZLM7
LEI
549300PC8MR6QHH6P296
EIN
04-3404176

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Thomas A. MCCOURTChief Executive Officer, Director1,898,838
Jeffrey SilberSVP, CMO, Head-Res&Drug137,036
Ronald SilverPFO & PAO755,250
Tammi L. GaskinsChief Commercial Officer350,350
Michael ShetzlineSVP, CMO, Head-Res&Drug1,179,462
Minardo JohnChief Legal Officer500,498
Gregory S. MartiniChief Financial Officer297,213
Sravan Kumar EmanySVP, COO and CFO309,572
Andrew DavisSVP, Chief Business Officer284,685
Alexander J. DennerDirector18,710,619
Jay ShepardDirector235,036
Jon R. DuaneDirector253,820
Julie McHughDirector272,320
Mark G. CurrieDirector676,900
Catherine MoukheibirDirector181,425
Marla L. KesslerDirector229,364
Andrew DreyfusDirector228,313

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.95M$1.29M$1.21M$27–
FY2024$6.08M-$4.49M$2.82M$36–
FY2023$7.58M$4.63M$2.62M$92–
FY2022$7.89M$10.16M$2.30M$93$111
FY2021
Mark Mallon
$170.58K-$8.68M$2.92M$88$125
FY2021
Thomas Mc Court
$8.81M$9.73M$2.92M$88$125

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Thomas McCourt
Chief Executive Officer
$867.57K$411.70K$650.68K$18.45K$1.95M-68%
Gregory Martini
Senior Vice President, Chief Financial Officer
$470.47K$447.78K$274.44K$18.45K$1.21M–
Tammi Gaskins
Senior Vice President, Chief Commercial Officer
$474.72K$447.78K$274.44K$18.45K$1.22M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 4, 2010
Offer price
$11.25
Securities offered
16,666,667
Gross proceeds
$187.50M
Exchange
Nasdaq
First trading day
Feb 3, 2010
First-day close
$11.65+3.6%
Lock-up ends (est.)
Aug 2, 2010

“The initial public offering price is $11.25 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 100 employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?